Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL3818 (anlotinib) plus paclitaxel vs chemotherapy in platinum‑resistant or platinum‑refractory ovarian, fallopian tube, or primary peritoneal cancer (Japan)
jRCT2031230010Phase 3Completed
- Sponsor
- Advenchen Laboratories
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of anlotinib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Advenchen Laboratories. Primary endpoint: Progression-Free Survival (PFS). Started May 2023; status: completed.
02
Drugs
anlotinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2031230010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230010.